Etifoxine (and therefore GRX-917) was recently shown to reduce neuroinflammation via inhibition of the NLRP3 inflammasome pathway (https://www.biorxiv.org/content/10.1101/2023.09.19.558428v1). Etifoxine inhibits the NLRP3 inflammasome pathway broadly, as shown by marked reductions of NLRP3, IL-1beta, and TNF. In addition, significant improvement in clinical scores were observed in the mouse EAE model of [...]
qEEG biomarkers demonstrated anxiolytic efficacy in both Phase 1 of GRX-917 and Phase 1 of etifoxine. qEEG Beta power increase Rapid-onset, sustained activity Time-dependent Exposure-dependent Increased qEEG Beta Power PD marker confirms GABAA receptor target engagement Anxiolytic efficacy biomarker For questions contact: Richard G. Farrell Chief Financial Officer Follow [...]
NEWPORT BEACH, CA – GABA Therapeutics, Inc has successfully completed the single ascending dose (SAD) stage of its Phase 1 study of GRX-917 in Melbourne, Australia. Interim data from the SAD stage showed that GRX-917 was well tolerated and favorable safety results were observed up to 500mg. Furthermore, the results [...]
NEWPORT BEACH, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- GABA Therapeutics, Inc, (“GABA”) a clinical-stage biotechnology company developing novel therapies for anxiety, depression and other neurological disorders, and part of the atai Life Sciences (“atai”) platform, announces the appointment of Mario David Saltarelli M.D., Ph.D. as Chief Executive Officer [...]
GABA Therapeutics has continued to progress the development of GRX-917 without any material impact from the COVID-19 pandemic. GABA Therapeutics recently completed its Phase 1 clinical trial of the anxiolytic etifoxine in Melbourne, Australia, on time and slightly ahead of budget. The two-stage, double-blind, placebo-controlled single and multiple dose [...]
DRUGS: $15.5M; XANAX IMPROVEMENT? Biotech with Anxiety Drug Lands Funding By Jessie Yount Orange Country Business Journal Monday, February 24, 2020 An effort to develop a new and improved version of an anti-anxiety drug—never commercialized in the U.S.—is underway in Newport Beach. Gaba Therapeutics Inc. has developed and patented a [...]
Today, GABA Therapeutics commenced dosing for its Phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia – right on schedule. The Phase I, two-stage, double-blind, placebo-controlled single and multiple dose study will evaluate the pharmacokinetics, pharmacodynamics, and safety of oral etifoxine in up to 34 normal healthy [...]
NEWPORT BEACH, Calif. and BERLIN, Sept. 20, 2019 /PRNewswire/ -- Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that promises [...]
